|
Originally published In Press as doi:10.1074/jbc.M109274200 on November 7, 2001
J. Biol. Chem., Vol. 277, Issue 5, 3440-3446, February 1, 2002
The Unique Solution Structure and Immunochemistry of the
Candida albicans -1,2-Mannopyranan Cell Wall
Antigens*,
Mark
Nitz ,
Chang-Chun
Ling ,
Albin
Otter ,
Jim E.
Cutler§¶, and
David R.
Bundle
From the Department of Chemistry, the University of
Alberta, Edmonton, Alberta T6G 2G2, Canada and the
§ Department of Microbiology, Montana State University,
Bozeman, Montana 59717-3520
Received for publication, September 25, 2001, and in revised form, November 2, 2001
 |
ABSTRACT |
Synthetic oligomers of the antigenic
Candida albicans (1 2)- -mannopyranans adopt a compact
solution conformation that leads to numerous inter-residue nuclear
Overhauser effects, including unprecedented nuclear Overhauser effects
between n and n + 3 residues. In excellent
agreement with experimentally determined distances, unrestrained
molecular dynamics point to a single family of conformations that
approximate a compact helical motif with a three-residue repeat for
this unique homopolymer. When the synthetic di- to hexasaccharides
were employed as inhibitors of monoclonal antibodies, which protect
mice against a lethal dose of the yeast pathogen, a novel pattern of
inhibitor activity was observed. Instead of the paradigm first reported
by Kabat (Kabat, E. A. (1962) Fed. Proc. 21, 694-701;
Kabat, E. A. (1966) J. Immunol. 97, 1-11), wherein homo-oligosaccharides exhibit increasing inhibitory activity with increasing size, here the maximum activity is reached for di- and
trisaccharides and diminishes significantly for tetra-, penta-, and
hexasaccharides. These immunochemical data correlate with the ordered
conformation of the -1,2-linked mannopyranan and imply that a
uniquely small antigenic determinant has potential as a component of
synthetic conjugate vaccines against Candida albicans.
 |
INTRODUCTION |
Monoclonal antibodies that protect mice against the pathogenic
yeast, Candida albicans (1-3), have been shown to be
specific for a cell wall (1 2)- -mannan antigen (4, 5). The unique immunochemical properties of this antigen correlate with its solution conformation and show a sharp contrast with the paradigm first reported
by Kabat (6, 7) some 40 years ago that applies to the majority of
oligosaccharide-antibody interactions.
C. albicans, the most common etiologic agent in candidiasis
(8), commonly affects immunocompromised patients and those undergoing
long term antibiotic treatment (9). The number of cases of systemic
candidiasis has become a major medical problem in hospitals, where
C. albicans is now responsible for up to 25% of nosocomial
infections (9). Treatment of these infections is becoming increasingly
difficult due to increased drug resistance against known antifungal
compounds (10). Humoral and cell-mediated immunity may both play a
major role in host defenses against C. albicans. Whereas
most patients with serious mucosal infections have defects in their
cellular immunity (11), patients with deep tissue invasion seem to lack
antibodies against the (1 2)- -mannan oligomer found in the yeast
cell wall (12).
Monoclonal antibodies raised against C. albicans cell wall
extracts in mice were protective against disseminated candidiasis and
vaginal candidiasis (1-3, 13). Further studies on these protective
monoclonal antibodies indicated the active antigen to be a
(1 2)- -mannan polymer that is present as a component of the cell
wall phosphomannan (14) and separately as a phospholipomannan (15). In
both forms the (1 2)- -mannan antigen is relatively small
consisting of between 2 and 14 residues (16). The immunochemistry and
solution properties of this antigen are of great interest because
(1 2)- -mannan oligomers have potential as the key epitope of
conjugate vaccines (17). Computational studies predicted that
homopolysaccharides with this linkage pattern would be of rare
occurrence and should exhibit a crumpled conformation to alleviate
steric contacts between remote residues (18). To investigate their
solution structure and immunochemical properties, a series of short
oligomers ranging from di- to hexasaccharides have been synthesized as
glycosides and glycoconjugates (Fig. 1)
(19, 20). Here the simple glycosides are used to develop a
conformational model of the oligosaccharides and to probe the
immunochemistry of -mannan-specific monoclonal antibodies that
protect mice against C. albicans.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 1.
Synthetic di- to hexasaccharide ligands 1-5
and the thio-linked congener 6. Individual ring systems are
labeled as shown in Fig. 3.
|
|
 |
EXPERIMENTAL PROCEDURES |
Materials--
Oligosaccharides 1-6 (Fig. 1) and
their corresponding conjugates with bovine serum albumin were
synthesized as reported elsewhere (19, 20). The monoclonal antibodies,
mAb B6.1 (IgM) and mAb C3.1 (IgG3), produced as concentrated tissue
culture supernatants and diluted ~1:40,000 (B6.1) and ~1:2000
(C3.1) for ELISA1
measurements have been described previously (1-3, 13).
Oligosaccharide Inhibition of Enzyme Immunoassay--
C.
albicans mannan (22) obtained by 2-mercaptoethanol extraction of
whole cells without subsequent affinity fractionation was dissolved in
PBS (10 µg/ml), and the solution was
used to coat 96-well ELISA plates (100 µl, 18 h at 4 °C). The
plate was washed five times with PBST (PBS containing Tween 20, 0.05%
v/v) and blocked for 1 h at room temperature (2% bovine serum
albumin/PBS, 100 µl). The monoclonal antibodies were mixed with
inhibitor dissolved in PBST at concentrations between 0.1 µM and 1 mM, and the resulting solutions were
added to the coated microtiter plate in triplicate and incubated at
room temperature for 18 h. The plate was washed with PBST (5 times), and goat anti-mouse (IgG or IgM) antibody conjugated to
horseradish peroxidase (diluted 1:2000, Kirkegaard & Perry
Laboratories) in PBST (100 µl) was added and incubated for 1 h
at room temperature. The plate was washed with PBST (5 times);
3,3',5,5'-tetramethylbenzidine (100 µl, Kirkegaard & Perry Laboratories) was added, and after 2 min the color reaction was stopped
by the addition of 1 M phosphoric acid (100 µl).
Absorbance was read at 450 nm, and percent inhibition was calculated
relative to wells containing antibody without inhibitor.
NMR Methods--
Experiments were carried out on Varian Inova
600- and 800-MHz spectrometers using indirect detection, 5-mm triple
resonance, z-gradient probes. Experimental conditions were
kept as similar as possible between the two spectrometers, except for
inherent field-related differences, and are described here for the
800-MHz data. The sample temperature was 25 °C for compounds
1-3 and 30 °C for compounds 4 and
5. The higher temperature moved the HOD peak upfield from
the anomeric signals. For data acquisition and processing VNMR 6.1B
software was used. Proton chemical shifts were measured relative to
external 0.1% acetone at 2.225 ppm. GCOSY and GTOCSY experiments were
record as described earlier (23, 24), the latter with a mixing time of
130 ms at a spin-lock field strength of 6.6 kHz. One scan for each of the 512 t1 incrementations was recorded with a sweep width
of 3700 Hz (4.6 ppm), digitized over 4300 data points.
Transmitter-based solvent presaturation was used during a 1.5-s
relaxation delay, and the acquisition time was 0.6 s. Acquisition
parameters for T-ROESY experiments (25) were essentially the same as
the ones described for the GTOCSY, except that 24 transients were
recorded with a total relaxation time of 2.1 s and a mixing time
of 400 ms at a spin-lock field of 4.2 kHz. The first two data points in
F2 were back-predicted by linear prediction, and no further base-line
corrections were applied (26).
Inter-proton Distances from Cross-peak Volumes--
Correlations
of interest were checked carefully for undesired TOCSY contributions
and integrated on both sides of the diagonal. To obtain a suitable
internal reference, the H1-H5 NOEs of each mannopyranose ring were
integrated on each side of the diagonal and averaged, and the resulting
value was set to 2.39 Å based on the distance found in relevant
crystal structures (27). Unknown inter-proton distances were then
calculated based on the usual r 6 NOE-distance
relationship. Some overlapping volumes could only be determined based
on the known relative intensities of multiplets that were partially
overlapped (an example is shown in Fig.
2D).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 2.
800-MHz 1H NMR spectra of
pentasaccharide 4. A, one-dimensional spectrum in
D2O showing excellent signal dispersion. B,
section of the two-dimensional GTOCSY experiment showing connectivities
through the entire spin system of ring E, starting from proton H2E.
C, section of the T-ROESY experiment showing correlations
from the anomeric proton H1E. D, expansion of region C
showing n + 2 (E-C) and n + 3 (E-B) as well as
some intra-residue NOE contacts.
|
|
Molecular Modeling--
Computer models were developed using the
Insight II molecular modeling package (version 2.9.5 from Molecular
Simulations Inc.) running on a Silicon Graphics Indigo II computer. All
energy calculations were carried out in vacuo with a
dielectric constant of 80.0 using the AMBER-plus force field with
exo-anomeric potentials (28). To locate a consensus minimum energy
conformation, an unrestrained simulated annealing protocol was used
(29). In brief, a high temperature-simulated annealing run generated 10 random energy structures. The ring geometries were enforced by scaling
the ring torsional energy terms by 7. These structures were then
separately cooled in 50 K steps, and at each step a 1-ps molecular
dynamics was performed from 500 to 300 K and then to 10 K in 10 K per
1-ps steps and finally to 5 K. Each annealed structure was then
minimized using a steepest descent algorithm. The lowest energy
structure was used for a 5-ns molecular dynamics run at 300 K. Theoretical time-averaged 1H-1H
(<r 6>) distances were then calculated using
MDPROCESS software.2
Tri- to pentasaccharides 2-4 and the thio-linked
tetrasaccharide 6 were modeled as outlined above. Details
for modeling the pentasaccharide 4 are provided below,
whereas further details related to the other structures 1-3
and 6 are available in the Supplemental Material.
 |
RESULTS |
NMR Chemical Shifts--
Unambiguous 1H and
13C chemical shifts for oligosaccharides 1-6
were established by a combination of GCOSY, GTOCSY, and HMQC
experiments. The most remarkable observation considering the
homo-polymeric nature of oligosaccharides 1-5 was the discrete signal dispersion in their 1H NMR spectra (Fig.
2A). The excellent dispersion of 1H signals
permits the spin system of each hexose residue of the homo-oligomers to
be assigned (Fig. 2, A and B). Although the resonances of protons H-1 to H-4 for each pyranose ring showed excellent dispersion (Table I), the H-5
and H-6 resonances exhibited severe overlap (not shown).
A comparison of the NMR data of the synthetic structures with data for
oligomers (30, 31) isolated from the yeast cell wall by acid hydrolysis
shows similar 1H and 13C chemical shifts
(Supplemental Material Tables I and II). Hemiacetals present in the
isolated oligomers cause chemical shift differences and considerable
spectral complexity, because both and forms of the terminal
residue exist and propagate chemical shift changes well beyond the
terminal reducing hexose residue (30, 31). Synthetic oligomers by
comparison are free of this complicating factor, because the terminal
mannose residue is protected as a -propyl glycoside.
NOE correlations between protons on either side of each glycosidic
linkage established the residue identity of the spin systems of
adjacent pyranose rings and confirmed their sequence within each linear
oligomer. NOEs were measured from T-ROESY spectra of the oligomers
(1-5) and revealed numerous contacts between non-contiguous
residues, as illustrated for pentasaccharide 4 (Fig.
3). The presence of contacts between
n + 2 and n + 3 residues is clearly evident in
Fig. 2D. All of the anticipated strong NOEs due to
inter-glycosidic contacts between H-1 and H-2 of adjacent residues were
present and easily quantified due to the signal dispersion of the H-1
and H-2 protons.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 3.
NOE contacts between non-contiguous residues
of pentasaccharide 4. Mannopyranose rings are labeled
alphabetically starting at the reducing terminus.
|
|
The T-ROESY cross-peak volumes were quantified for the tri-, tetra-,
and pentasaccharide (2-4) and for the thio-linked tetrasaccharide 6. These data were used to derive
conformationally averaged inter-proton distances (Table
II). Hexasaccharide 5 exhibited spectral overlap of several important resonances, and the ROE
contacts from this structure were not quantified. Similar distances
observed across the glycosidic linkages of the oligomers 1-4 and 6 are indicative of compact, repetitive solution structures. The distances also suggest the inferred structure is not just a result of steric interactions between distant,
non-contiguous residues but represent a population of low energy
conformations with similar torsional angles about the glycosidic
linkages. If steric interactions between non-contiguous residues
were limiting the conformations of the oligomers, the shorter oligomers
would be expected to have distances that differ from those of the
higher molecular weight counterparts.
View this table:
[in this window]
[in a new window]
|
Table II
NOE contacts for (1 2)- -mannopyranosyl tri-, tetra-,
pentasaccharides 2-4, and thio-linked tetrasaccharide
6
|
|
Molecular Modeling--
Unrestrained molecular dynamics were
carried out for oligomers 2-4 and for the thio-analogue
6, and the resulting model for the pentasaccharide
4 is discussed below (data for the other oligomers are
available in the Supplemental Material, Table
III and Figs. 1-4).
Comparison of the 10 structures of the pentasaccharide obtained from
the simulated annealing protocol showed a single family of low energy
conformations (Fig. 4A). A
static model of the pentasaccharide in one of these conformations shows
the helical nature of this polysaccharide (Fig. 4B). The
three-dimensional repeating unit approximates three mannose residues.
This is illustrated by a CPK model of a tricolor repeat that
displays the residue repeating nature of the helix type structure (Fig.
4C).

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 4.
Structure of annealed pentasaccharide
4. A, structures of the low energy family generated from the
simulated annealing run. B, tube model (stereo) of the
lowest energy structure from A. C, CPK surface
(stereo) of the lowest energy structure (shown in B) with
green-red-blue-green-red coloring of sequential hexose
residues to indicate the near 3-residue helical repeat.
|
|
Theoretical inter-proton distances were calculated from the 5-ns
molecular dynamics run performed at 300 K. The data compared well with
distances determined from experimental NOEs (Table III) (29). During
the dynamics run, the oligosaccharide stayed within the range of
glycosidic torsional angles represented by the family of conformations
generated by simulated annealing.
A comparison of the conformations and molecular dynamics of the tri-,
tetra-, and pentasaccharides shows similar low energy conformations for
each of the oligosaccharides 2-4. The thio-linked
oligosaccharide 6 showed two minimum energy structures about
the terminal thioglycosidic linkage. Two conformations are explored at
angles centered about the two gauche conformations 60° and
60°. The first of these would be favored by the
exo-anomeric effect, but the force field was not
parameterized for the magnitude of this effect in the case of sulfur.
Although expected based on the findings of others (32-37) which show
thioglycosides to be more flexible than their O-linked
counterparts, the anti-conformer was not sampled during the MD
calculations of the thio-linkage ( , trajectory maps generated
from the molecular dynamics for each glycosidic linkage are
available in the Supplemental Material, Fig. 4).
Antibody Binding to Synthetic Glycans--
The affinity of IgM and
IgG monoclonal antibodies, generated by immunization of mice with
liposomal extracts of the C. albicans cell wall, for the
synthesized propyl glycosides 1-6 was determined by
competitive ELISA (Table IV).
View this table:
[in this window]
[in a new window]
|
Table IV
Inhibition by synthetic oligosaccharides 1-6 of the
binding of monoclonal antibodies B6.1 (IgM) and C3.1 (IgG) to
C. albicans mannan antigen
|
|
The IgM antibody, B6.1, showed a surprisingly high affinity for the di-
and trisaccharides when compared with tetrasaccharide 3, pentasaccharide 4, and hexasaccharide 5 (Table 4 and Fig. 5). The inhibitory power of the
propyl
1-thio- -D-mannopyranosyl- -D-mannopyranotrioside 6 fell between that of the tri- and tetrasaccharide (Table IV).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 5.
ELISA inhibition data for monoclonal
antibodies B6.1 (A) and C3.1
(B). Inhibition by synthetic oligosaccharides
1-5 of monoclonal antibody binding to C. albicans extract. , propyl
(1 2)- -D-mannopyranobioside (1); ,
propyl (1 2)- -D-mannopyraontrioside (2);
, propyl
(1-thio- -D-mannopyranosyl)-(1 2)- -D-mannopyranotrioside
(6); , propyl
(1 2)- -D-mannopyranotetroside (3); ,
propyl (1 2)- -D-mannopyranopentoside (4);
, propyl (1 2)- -D-mannopyranohexoside
(5).
|
|
The same panel of oligomannosides 1-6 with IgG (C3.1)
antibody showed a trend in affinities similar to those observed with
mAb B6.1. Again di- and trisaccharides had the highest affinities but
were 5- and 2-fold higher than for B6.1 (Table IV). The other (1 2)- -oligomannosides had similar affinities (Fig. 5).
 |
DISCUSSION |
The chemical synthesis (19, 20) of oligomers of the
(1 2)- -mannan has provided a series of compounds locked in the
anomeric configuration of the native antigen, thereby facilitating a
thorough analysis of the solution structure and immunochemical
properties of this important C. albicans antigen.
The excellent signal dispersion observed for the proton resonances of
the (1 2)- -mannopyranan oligomers 1-5 suggests they
are conformationally distinct, in contrast to other homo-oligomers such
as (1 2)- -mannopyranotetrose (38) or maltoheptose
((1 4)- -glucopyranoheptose) (39), where the conformationally
sensitive H-1 resonances have similar chemical shifts. Most
homopolysaccharides exhibit this degeneracy in chemical shift (40, 41),
because internal residues sample virtually identical chemical
environments. The distinct 1H chemical shifts observed for
the H-1 and H-2 resonances of each mannose residue of tetrasaccharide
3 suggest that oligomeric (1 2)- -mannopyranans are
conformationally distinct in contrast to many homo-oligomers. Similar
exceptions occur for both the - and -1,2-linked oligomers of
glucose (42, 43). These two examples and the (1 2)- -mannopyranan
were identified by modeling studies as belonging to a class of
homopolymers that would be expected to form relatively stiff and
crumpled conformations (18). Chemical shift characteristics of
oligomers isolated from C. albicans cell walls have been
noted and tentatively interpreted in terms of a collapsed conformation
(44).
The use of NOEs to define solution conformations of oligosaccharides is
most effective when there are numerous NOEs between hexose residues.
This occurs for well defined oligosaccharide conformations that most
often result from branching through vicinal substitution, as is the
case with the blood group A and B antigens. In this and other such
structures (45-47), NOE contacts between non-contiguous residues (for
example n and n + 2) often occur spanning the
branched pyranose ring. A linear homopolysaccharide can achieve the
equivalent of vicinal substitution only if the hydroxyl group adjacent
to the anomeric center is the site for chain extension. For aldohexoses
this occurs for 1,2-linkages. However, many 1,2-linked homo-oligomers
such as those of the Brucella abortus A antigen yield few if
any NOE contacts between non-contiguous residues (48). The observation
of multiple NOE contacts between non-contiguous residues in the
(1 2)- -mannopyranans studied here is exceptional in
oligosaccharide conformational analysis. The presence of NOE
interactions between residues residues A and D (n to
n + 3 contacts) is to our knowledge unprecedented and
indicative of a compact structure.
Unrestrained molecular dynamics of the mannopyranans generated a
discrete model of these unique oligosaccharides, which agreed well with
the NOE measurements. A comparison of the conformational space sampled
by the oligosaccharides indicates that the tri-, tetra-, and
pentasaccharides explore very similar torsional angles across all their
linkages. The family of conformations sampled is consistent with a
model that imparts helical character to this glycan chain (Fig. 4). The
repeating unit is approximately 3 residues long, but due to the
inherent flexibility about glycosidic torsional angles, the overlap of
residues n and n + 3 is only approximate (Supplemental Material Fig. 5). In this family of conformations, hydroxyls are oriented into solution, and a hydrophobic core is made up
of the -faces of the mannose rings. It is of interest to note that
after this work was completed a different chemical synthesis of the
(1 2)- -mannopyranan oligosaccharides was reported, together with a
crystal structure of a tetrasaccharide with attached organic protecting
groups (49). The gross features of this molecule appear to be very
closely related to the aqueous solution structure proposed here.
It is of interest to consider possible implications of this
oligosaccharide structure. The helix hides the glycosidic linkages at
its core possibly limiting the accessibility to endomannosidases. The
hydrophobic faces of the rings are also shielded, except for the
terminal residues, which likely have implications for the binding of
oligomers by antibodies or lectins, where hydrophobic surfaces can be important.
The distinctive conformation of the -1,2-linked pyranomannans
correlates with the unique immunochemistry of these oligomers. Di- and
trisaccharides 1 and 2 exhibit significantly higher affinity for the monoclonal antibodies than larger tetra- to
hexasaccharides (3-5). In fact the tetrasaccharide
3 and hexsaccharide 5 are 10 and 100 times poorer
inhibitors of IgG (monoclonal antibody C3.1) binding to the cell wall
mannan than disaccharide 1. Similar trends are observed for
the IgM antibody (B6.1), although here trisaccharide 2 is a marginally better inhibitor than disaccharide 1. This size specificity can be contrasted with the findings of Kabat (6, 7), who
showed for human polyvalent sera raised against the homopolymeric
dextran antigen that the inhibitory power of oligosaccharides steadily
increased as the size of an inhibitor increased and reached a plateau
at about the size of a hexamer.
Of the two general types of antibody-binding site, groove and cavity,
predicted for carbohydrate epitopes, the groove-type might be expected
to show epitope activity that steadily increases with ligand size.
Indeed, when the small energetic gains that can arise from pyranose
residues that flank the antigenic determinant are considered, the
optimal size of the inhibitor, found by Kabat (6, 7), correlates well
with the size of oligosaccharides that fill the binding sites of
groove-type antibodies studied by crystallography (50-55). Exceptions
to this generality are seen for certain homo- and heteropolysaccharides
containing sialic acid where a unique bioactive conformation dictates a
more pronounced dependence on oligomer length (56-58). The C. albicans antibodies do not conform to the characteristics of the
second type of binding site. Cavity sites typically recognize the
terminal sugars of a polymeric chain in a manner similar to that
described for the crystal structure of the Vibrio cholerae
carbohydrate epitope complexed with a monoclonal antibody (55). In this
complex the terminal residue of the polysaccharide antigen contributes
90% of the binding energy, and inhibitors to this type of chain end specific antibody are expected to show inhibition data that are virtually unchanged on a molar basis as ligand molecular weight increases (59). However, there is no precedence for sharply decreasing
inhibitory power with increasing oligosaccharide size.
The immune response to (1 2)- -mannopyranans is unique in two ways.
(i) The larger tetra- to hexasaccharides do not possess the same
epitope as smaller oligomers and therefore have weaker affinity for the
antibodies. (ii) In the case of the protective antibodies, the immune
system has selected for antibodies against short oligomers.
The first point is borne out for structures determined by NMR and
molecular modeling. Due to the helical nature of the oligomers, antibodies raised against the short oligomers (2-3 residues) may experience steric conflicts when binding larger oligomers, because the
fourth residue is in close proximity to the first residue. There is
precedence for steric effects, because residues flanking an
antibody-binding site can be forced to adopt higher energy conformations to relieve steric interactions with the surface of the
antibody (60). The presence of a steric interaction with the fourth
residue of the oligomer is consistent with the higher activity of the
thio-linked tetrasaccharide 6 over its O-linked
analogue 3, an atypical observation for thioglycoside mimetics, which usually bind their protein receptors with lower affinity (35). Due to the increased flexibility of the thioglycosidic bond (Supplemental Material), the terminal residue is better able to
relieve its steric interaction with the antibody-binding site by
adopting other low energy conformations that place the terminal mannopyranose ring away from the antibody surface.
Second, protective monoclonal antibodies recognize short
oligosaccharide sequences or the terminal hexose residues of larger oligomers. It is surprising that both protective antibodies of different immunoglobulin subclasses show similar affinities for the
synthetic oligomers and therefore recognize the natural oligomers in a
similar fashion. Given the conformation of the oligosaccharides, it may
be difficult for an antibody to recognize internal residues of the
oligomer, and in this sense the conformation of the antigen dictates
the immune response to it. If the internal residues were recognized,
such antibodies could be forced to bind non-contiguous residues, which
would be entropically disfavored due to the higher degrees of freedom
between non-contiguous residues (this can be most readily appreciated
by examining a model of an undecasaccharide, Supplemental Material
Fig. 5).
Expression of significant amounts of low molecular weight antigen may
account for the induction of protective antibodies C3.1 and B6.1. In
fact, analysis of the relative abundance of (1 2)- -mannopyranans by fluorophore-assisted carbohydrate electrophoresis points to a high
incidence of di- and trisaccharide epitopes in the acid-sensitive portion of the mannan (61).
These findings have direct implications for the design of anti-C.
albicans conjugate vaccines. It has been suggested that intermediate sized oligosaccharides (15-20 hexose residues in length)
are required for the carbohydrate component of conjugate vaccines
designed to prevent bacterial diseases (62, 63). The underlying
assumption was that protein-conjugated oligosaccharide should be of
sufficient size to assume a conformation similar to its native state on
the bacterial cell surface. Commercial carbohydrate-based conjugate
vaccines are for the most part developed from isolated polysaccharides
rather than defined synthetic oligomers (64). Only recently have
chemical methods reached the sophistication to tackle the synthesis of
such large oligosaccharide targets (65). In the case of
(1 2)- -mannopyranans of the yeast cell wall, it appears that the
size of the epitope that induces protective antibody falls within the
range of 2-3 hexose residues, which is significantly smaller than the
15-20 sugar residues required to create a practical immunogen that can
induce polysaccharide-specific antibodies effective against pathogenic
organisms (62, 64). In the case of the 2,8-linked sialic acid capsule
of Neisseria meningitidis and related polysaccharides
with sialic acid-containing epitopes, the size requirement can be even
larger than 15-20 sugar residues, because the immunizing epitope must
be part of a shallow helical determinant present in the native antigen
(21, 56, 57, 66, 67).
On the basis of its helical conformational and immunochemical
properties, and in sharp contrast to the preceding examples, we suggest
that a small di- or trisaccharide or suitable analogues of the type
described here coupled to protein will provide an antigen sufficient
for protection against C. albicans.
 |
ACKNOWLEDGEMENTS |
We thank Joanna Sadowska for technical
support. NMR spectra at 800 MHz were obtained at the Canadian National
High Field NMR Center funded by the Canadian Institutes of Health
Research, National Science and Engineering Research Council of
Canada, Alberta Heritage Foundation for Medical Research, and the
University of Alberta.
 |
FOOTNOTES |
*
This work was supported in part by research grants from the
National Science and Engineering Research Council of Canada (to D. R. B.), the University of Alberta, and National Science and Engineering Research Council of Canada postgraduate studentship awards
(to M. N.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The on-line version of this article (available at
http://www.jbc.org) contains Tables I-III and Figs.
1-5.
¶
Supported by National Institutes of Health Research
Grants RO1 AI24912, RO1 DE13982, and PO1 AI37194.
To whom correspondence should be addressed: Dept. of
Chemistry, the University of Alberta, Edmonton, Alberta T6G 2G2,
Canada. Tel.: 780-492-8808; Fax: 780-492-7705; E-mail:
Dave.Bundle@ualberta.ca.
Published, JBC Papers in Press, November 7, 2001, DOI 10.1074/jbc.M109274200
2
T. J. Rutherford, unpublished software.
 |
ABBREVIATIONS |
The abbreviations used are:
ELISA, enzyme-linked
immunosorbent assay;
PBS, phosphate-buffered saline;
NOE, nuclear
Overhauser effect;
mAb, monoclonal antibody.
 |
REFERENCES |
| 1.
|
Han, Y.,
and Cutler, J. E.
(1995)
Infect. Immun.
63,
2714-2719[Abstract]
|
| 2.
|
Han, Y.,
and Cutler, J. E.
(1997)
J. Infect. Dis.
175,
1169-1175[Medline]
[Order article via Infotrieve]
|
| 3.
|
Han, Y.,
Riesselman, M. H.,
and Cutler, J. E.
(2000)
Infect. Immun.
68,
1649-1654[Abstract/Free Full Text]
|
| 4.
|
Shibata, N.,
Kobayashi, H.,
Tojo, M.,
and Suzuki, S.
(1986)
Arch. Biochem. Biophys.
251,
697-708[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Shibata, N.,
Fukasawa, S.,
Kobayashi, H.,
Tojo, M,
Yonezu, T.,
Ambo, A.,
Ohkubo, Y.,
and Suzuki, S.
(1989)
Carbohydr. Res.
187,
239-253[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Kabat, E. A.
(1962)
Fed. Proc.
21,
694-701
|
| 7.
|
Kabat, E. A.
(1966)
J. Immunol.
97,
1-11[Abstract/Free Full Text]
|
| 8.
|
Casadevall, A.,
Cassone, A.,
Bistoni, F.,
Cutler, J. E.,
Magliani, W.,
Murphy, J. W.,
Polonelli, L.,
and Romani, L.
(1998)
Med. Mycol.
36 Suppl. 1,
95-105
|
| 9.
|
Beck-Sagué, C. M.,
and Jarvis, W. R.
(1993)
J. Infect. Dis.
167,
1247-1251[Medline]
[Order article via Infotrieve]
|
| 10.
|
Odds, F. C.
(1996)
Int. J. Antimicrob. Agents
6,
145-147
|
| 11.
|
Levitz, S. M.
(1992)
Clin. Infect. Dis.
14,
37-42
|
| 12.
|
Jouault, T.,
Delaunoy, C.,
Sendid, B.,
Ajana, F.,
and Poulain, D.
(1997)
Clin. Diagn. Lab. Immunol.
4,
328-333[Abstract]
|
| 13.
|
Han, Y.,
Kozel, T. R.,
Zhang, M. X.,
MacGill, R. S.,
Carroll, M. C.,
and Cutler, J. E.
(2001)
J. Immunol.
167,
1550-1557[Abstract/Free Full Text]
|
| 14.
|
Han, Y.,
Kanbe, T.,
Cherniak, R.,
and Cutler, J. E.
(1997)
Infect. Immun.
65,
4100-4107[Abstract]
|
| 15.
|
Trinel, P.-A.,
Plancke, Y.,
Gerold, P.,
Jouault, T.,
Delplace, F.,
Shwarz, R. T.,
Strecker, G.,
and Poulain, D.
(1999)
J. Biol. Chem.
274,
30520-30526[Abstract/Free Full Text]
|
| 16.
|
Trinel, P. A.,
Lepage, G.,
Joulault, T.,
Strecker, G.,
and Poulain, D.
(1997)
FEBS Lett.
416,
203-206[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Han, Y.,
Melinda, A.,
and Cutler, J. E.
(1999)
J. Infect. Dis.
179,
1477-1484[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
| Rees, D. A., and Scott, W. E. (1971) J. Chem.
Soc. 469-479
|
| 19.
|
Nitz, M.,
and Bundle, D. R.
(2001)
J. Org. Chem.
66,
8411-8423[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Nitz, M.,
and Bundle, D. R.
(2000)
Org. Lett.
2,
2939-2942[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Brisson, J.-R.,
Baumann, H.,
Imberty, A.,
Perez, S.,
and Jennings, H. J.
(1992)
Biochemistry
31,
4996-5004[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Kanbe, T.,
Han, Y.,
Redgrave, B.,
Riesselman, M. H.,
and Cutler, J. E.
(1993)
Infect. Immun.
61,
2578-2584[Abstract/Free Full Text]
|
| 23.
|
Hurd, R. E.
(1990)
J. Magn. Reson.
87,
422-428
|
| 24.
|
Otter, A.,
Hindsgaul, O.,
and Bundle, D. R.
(1995)
Carbohydr. Res.
275,
381-389[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Hwang, T.-L.,
and Shanka, A. J.
(1992)
J. Am. Chem. Soc.
114,
3157-3159[CrossRef]
|
| 26.
|
Babcook, D. M.,
Sahasrabudhe, P. V.,
and Gmeiner, W. H.
(1996)
Magn. Reson. Chem.
34,
851-857[CrossRef]
|
| 27.
|
Jeffrey, G. A.,
McMullan, R. K.,
and Takagi, S.
(1977)
Acta Crystallogr. Sect. B Struct. Sci.
33,
728-737[CrossRef]
|
| 28.
|
Homans, S. W.
(1990)
Biochemistry
29,
9110-9118[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Rutherford, T. J.,
Spackman, D. G.,
Simpson, P. J.,
and Homans, S. W.
(1994)
Glycobiology
4,
59-68[Abstract/Free Full Text]
|
| 30.
|
Shibata, N.,
Hisamichi, K.,
Kobayashi, H.,
and Suzuki, S.
(1993)
Arch. Biochem. Biophys.
302,
113-117[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Faille, C.,
Wieruszeski, J.-M.,
Michalski, J.-C.,
Poulain, D.,
and Strecker, G.
(1992)
Carbohydr. Res.
236,
17-27[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
| Montero, E., Garcia-Herrero A., Asenso, J. L., Hirai, K., Ogawa,
S., Santoyo-González, Canada, J. F., and
Jiménez-Barbero, J. (2000) Eur. J. Org. Chem.
1945-1952
|
| 33.
|
Anuilera, B.,
Jiménez-Barbero, J.,
and Fernández-Mayoralas, A.
(1998)
Carbohydr. Res.
308,
19-27[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Montero, E.,
Vallmitjana, M.,
Pérez-Pons, J. A.,
Querol, E.,
Jiménez-Barbero, J.,
and Canada, F. J.
(1998)
FEBS Lett.
421,
243-248[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Nilsson, U.,
Johansson, R.,
and Magnusson, G.
(1996)
Chem. Eur. J.
2,
295-302
|
| 36.
|
Geyer, A.,
Hummel, G.,
Eisele, T.,
Reinhardt, S.,
and Schmidt, R. R.
(1996)
Chem. Eur. J.
2,
981-988
|
| 37.
|
Bock, K.,
Duus, J. Ø.,
and Refn, S.
(1994)
Carbohydr. Res.
253,
51-61[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Ogawa, T.,
and Yamamoto, H.
(1982)
Carbohydr. Res.
104,
271-283[CrossRef]
|
| 39.
|
Sugiyama, H.,
Toyohiko, N.,
Horii, M.,
Motohashi, K.,
Sakai, J.,
Usui, T.,
Hisamichi, K.,
and Ishiyama, J.
(2000)
Carbohydr. Res.
325,
177-182[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Caroff, M.,
Bundle, D. R.,
Perry, M. B.,
Cherwonogrodzky, J. W.,
and Duncan, J. R.
(1984)
Infect. Immun.
46,
384-388[Abstract/Free Full Text]
|
| 41.
|
Kihlberg, J.,
and Bundle, D. R.
(1991)
Carbohydr. Res.
216,
67-78[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Ogawa, T.,
and Takanashi, Y.
(1983)
Carbohydr. Res.
123,
C16-C18[CrossRef]
|
| 43.
|
Pozsgay, V.,
and Robbins, J. B.
(1995)
Carbohydr. Res.
277,
51-66[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Shibata, N.,
Hisamichi, K.,
Kikuchi, T.,
Kobayashi, H.,
Okawa, Y.,
and Suzuki, S.
(1992)
Biochemistry
31,
5680-5686[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Otter, A.,
Lemieux, R. U.,
Ball, R. G.,
Venot, A. P.,
Hindsgaul, O.,
and Bundle, D. R.
(1999)
Eur. J. Biochem.
259,
295-303[Medline]
[Order article via Infotrieve]
|
| 46.
|
Lemieux, R. U.,
Bock, K.,
Delbaere, L. T. J.,
Koto, S.,
and Rao, V. S.
(1980)
Can. J. Chem.
58,
631-653[CrossRef]
|
| 47.
|
Bock, K.,
Meldal, M.,
Bundle, D. R.,
Iversen, T.,
Pinto, B. M.,
Garegg, P. J.,
Kvanström, I.,
Norberg, T.,
Lindberg, A. A.,
and Svenson, S. B.
(1984)
Carbohydr. Res.
130,
35-53[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Peters, T.,
Brisson, J.-R.,
and Bundle, D. R.
(1990)
Can. J. Chem.
68,
979-988[CrossRef]
|
| 49.
|
Crich, D., Li., H.,
Yao, Q.,
Wink, D. J.,
Sommer, R. D.,
and Rheingold, A. L.
(2001)
J. Am Chem. Soc.
123,
5826-5828[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Cygler, M.,
Rose, D. R.,
and Bundle, D. R.
(1991)
Science
253,
442-446[Abstract/Free Full Text]
|
| 51.
|
Rose, D. R.,
Przybylska, M., To, R. J.,
Kayden, C. S.,
Oomen, R. P.,
Vorberg, E.,
Young, N. M.,
and Bundle, D. R.
(1993)
Protein Sci.
2,
1106-1113[Medline]
[Order article via Infotrieve]
|
| 52.
|
Vyas, M. N.,
Vyas, N. K.,
Meikle, P. J.,
Sinnott, B.,
Pinto, B. M.,
Bundle, D. R.,
and Quiocho, F. A.
(1993)
J. Mol. Biol.
231,
133-136[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Bundle, D. R.
(1998)
in
Carbohydrates
(Hecht, S., ed)
, pp. 370-440, Oxford University Press Inc., Oxford
|
| 54.
|
Jeffrey, P. D.,
Bajorath, J.,
Chang, C. Y.,
Yelton, D.,
Hellstrom, I.,
Hellstrom, K. E.,
and Sheriff, S.
(1995)
Nat. Struct. Biol.
2,
466-471[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Villeneuve, S.,
Souchon, H.,
Riottot, M.-M.,
Mazié, J.-C.,
Lei, P.-S.,
Glaudemans, C. P. J.,
Ková, P.,
Fournier, J.-M.,
and Alzari, P. M.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
8433-8438[Abstract/Free Full Text]
|
| 56.
|
Wessels, M. R.,
Muñoz, A.,
and Kasper, D. L.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
9170-9174[Abstract/Free Full Text]
|
| 57.
|
Michon, F.,
Brisson, J.-R.,
and Jennings, H. J.
(1987)
Biochemistry
26,
8399-8405[CrossRef][Medline]
[Order article via Infotrieve]
|
| 58.
|
Evans, S. V.,
Sigurskjold, B. W.,
Jennings, H. J.,
Brisson, J.-R., To, R.,
Altman, E.,
Frosch, M.,
Weisgerber, C.,
Kratzin, H.,
Klebert, S.,
Vaesen, M.,
Bitter-Suermann, D.,
Rose, D. R.,
Young, N. M.,
and Bundle, D. R.
(1995)
Biochemistry
34,
6737-6744[CrossRef][Medline]
[Order article via Infotrieve]
|
| 59.
|
Glaudemans, C. P. J.
(1991)
Chem. Rev.
91,
25-33[CrossRef]
|
| 60.
|
Milton, M. J.,
and Bundle, D. R.
(1998)
J. Am. Chem. Soc.
120,
10547-10548[CrossRef]
|
| 61.
|
Goins, T. L.,
and Cutler, J. E.
(2000)
Infect. Immun.
38,
2862-2869
|
| 62.
|
Mäkelä, O.,
Peterfy, F.,
Outschoorn, I. G.,
Richter, A. W.,
and Seppälä, I.
(1984)
Scand. J. Immunol.
19,
541-550[CrossRef][Medline]
[Order article via Infotrieve]
|
| 63.
|
Mäkelä, O.,
Seppälä, I.,
and Pelkonen, J.
(1985)
Eur. J. Biochem.
15,
827-833
|
| 64.
|
Pozsgay, V.
(1980)
Adv. Carbohydr. Chem. Biochem.
56,
153-199
|
| 65.
|
Pozsgay, V.,
Chu, C.,
Pannell, L.,
Wolfe, J.,
Robbins, J. B.,
and Schneerson, R.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
5194-5197[Abstract/Free Full Text]
|
| 66.
|
Brisson, J.-R.,
Uhrinova, S.,
Woods, R. J.,
van der Zwan, M.,
Jarrell, H. C.,
Paoletti, L. C.,
Kasper, D. L.,
and Jennings, H. J.
(1997)
Biochemistry
36,
3278-3292[CrossRef][Medline]
[Order article via Infotrieve]
|
| 67.
|
Zou, W.,
Mackenzie, R.,
Therien, L.,
Hirama, T.,
Yang, Q.,
Gidney, M. A.,
and Jennings, H. J.
(1999)
J. Immunol.
163,
820-825[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
E. Maes, C. Mille, X. Trivelli, G. Janbon, D. Poulain, and Y. Guerardel
Molecular Phenotyping of Mannosyltransferases-Deficient Candida albicans Cells by High-Resolution Magic Angle Spinning NMR
J. Biochem.,
April 1, 2009;
145(4):
413 - 419.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Xin, S. Dziadek, D. R. Bundle, and J. E. Cutler
Synthetic glycopeptide vaccines combining {beta}-mannan and peptide epitopes induce protection against candidiasis
PNAS,
September 9, 2008;
105(36):
13526 - 13531.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Mille, P. Bobrowicz, P.-A. Trinel, H. Li, E. Maes, Y. Guerardel, C. Fradin, M. Martinez-Esparza, R. C. Davidson, G. Janbon, et al.
Identification of a New Family of Genes Involved in {beta}-1,2-Mannosylation of Glycans in Pichia pastoris and Candida albicans
J. Biol. Chem.,
April 11, 2008;
283(15):
9724 - 9736.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Xin and J. E. Cutler
Hybridoma Passage In Vitro May Result in Reduced Ability of Antimannan Antibody To Protect against Disseminated Candidiasis
Infect. Immun.,
July 1, 2006;
74(7):
4310 - 4321.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. L. Granger, M. L. Flenniken, D. A. Davis, A. P. Mitchell, and J. E. Cutler
Yeast wall protein 1 of Candida albicans
Microbiology,
May 1, 2005;
151(5):
1631 - 1644.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Mille, G. Janbon, F. Delplace, S. Ibata-Ombetta, C. Gaillardin, G. Strecker, T. Jouault, P.-A. Trinel, and D. Poulain
Inactivation of CaMIT1 Inhibits Candida albicans Phospholipomannan {beta}-Mannosylation, Reduces Virulence, and Alters Cell Wall Protein {beta}-Mannosylation
J. Biol. Chem.,
November 12, 2004;
279(46):
47952 - 47960.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. P. Hobson, C. A. Munro, S. Bates, D. M. MacCallum, J. E. Cutler, S. E. M. Heinsbroek, G. D. Brown, F. C. Odds, and N. A.R. Gow
Loss of Cell Wall Mannosylphosphate in Candida albicans Does Not Influence Macrophage Recognition
J. Biol. Chem.,
September 17, 2004;
279(38):
39628 - 39635.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Ralton, T. Naderer, H. L. Piraino, T. A. Bashtannyk, J. M. Callaghan, and M. J. McConville
Evidence That Intracellular {beta}1-2 Mannan Is a Virulence Factor in Leishmania Parasites
J. Biol. Chem.,
October 17, 2003;
278(42):
40757 - 40763.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|